CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 37.28×, higher than 95% of its Biotechnology peers (median 5.28×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.05BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.05xvs all stocks
52-Week Change
62.23%vs all stocks
Market Capitalization
2.05BUSDvs all stocks (USD)
Enterprise Value
1.73BUSDvs all stocks (USD)
Forward P/E
-24.97xvs Biotechnology peers
Price to Book (MRQ)
6.38xvs Biotechnology peers
Enterprise to EBITDA
-29.20xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-13.82%vs Biotechnology peers
Return on Equity (TTM)
-19.66%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 28, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-59.42MUSDvs all stocks (USD)
Net Income (TTM)
-51.11MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-52.63MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-33.28MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-49.33MUSDvs all stocks (USD)
Pre-tax Income
-42.82MUSDFY2025 · Dec 31, 2025Income Tax Expense
-64.00KUSDFY2025 · Dec 31, 2025Net Income
-42.76MUSDFY2025 · Dec 31, 2025EBIT
-42.82MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-42.68MUSDFY2025 · Dec 31, 2025Research & Development
33.48MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
15.85MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
6.54MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
0.00USDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-42.76MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-37.56MUSDFY2025 · Dec 31, 2025Free Cash Flow
-37.58MUSDDerived from operating cash flow minus capital expenditure. This filing charges 144K of depreciation against 12K of capital expenditure, and its own free-cash-flow line reads -42.1M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
18.91MUSDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-42.76MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
144.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
5.18MUSDFY2025 · Dec 31, 2025Other Non-cash Items
463.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-598.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-12.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-170.66MUSDFY2025 · Dec 31, 2025Sale of Investments
76.57MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-94.11MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-11.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-84.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
108.06MUSDFY2025 · Dec 31, 2025Shares Outstanding
141.98MSharesUpdated Sep 28, 2026Float Shares
118.32MSharesUpdated Sep 28, 2026Shares Short
12.07MSharesUpdated Sep 28, 2026Short Ratio
8.30daysvs all stocks
Short % of Shares Outstanding
9.40%vs all stocks
% Held by Insiders
0.63%vs all stocks
% Held by Institutions
107.64%vs all stocks
Total Cash (MRQ)
318.87MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.24USDUpdated Sep 28, 2026Total Debt (MRQ)
605.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0019xvs Biotechnology peers
Current Ratio (MRQ)
37.28xvs Biotechnology peers
Book Value per Share (MRQ)
2.26USDUpdated Sep 28, 2026Total Assets
193.44MUSDvs all stocks (USD)
Total Current Assets
191.66MUSDFY2025 · Dec 31, 2025Total Liabilities
10.20MUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.78MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
446.00KUSDFY2025 · Dec 31, 2025Total Current Liabilities
9.75MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
18.91MUSDFY2025 · Dec 31, 2025Other Short-term Investments
169.35MUSDFY2025 · Dec 31, 2025Accounts Payable
3.91MUSDFY2025 · Dec 31, 2025Short-term Debt
307.00KUSDFY2025 · Dec 31, 2025Long-term Debt
446.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
128.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-329.80MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
183.24MUSDvs all stocks (USD)
52-Week Low
8.46USDUpdated Sep 28, 202652-Week High
20.22USDUpdated Sep 28, 202652-Week Change
62.23%vs all stocks
Beta
1.05xvs all stocks
50-Day MA
17.21USDUpdated Sep 28, 2026200-Day MA
14.24USDUpdated Sep 28, 2026Avg 10-Day Volume
1.68MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.51MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-0.3500USDUpdated Sep 28, 2026Other Income / Expense
-31.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 37.28×, higher than 95% of its Biotechnology peers (median 5.28×)Significant
Current ratio: 37.28Industry median: 5.28Industry P95: 22.31Peers compared: 193
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.12×)Notable
Debt-to-equity: 0.00Industry median: 0.12Industry P5: 0.00Peers compared: 193
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.78
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Market cap is $2.05B, above the global median of $1.18BNotable
Market cap (USD): 2,053,076,868Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Alvotech S.A.
Tier 1ProductionApproval-Gated PipelineRule
Voronoi, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Vericel Corporation
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Vazyme Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inspire Medical Systems, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Anke Biotechnology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kodiak Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ab&B Bio-Tech Co., Ltd. (JS)
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Kangtai Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Finolex Industries Ltd.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityLow-Leverage Liquidity Configuration
Fulgent Genetics Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityLow-Leverage Liquidity Configuration
Blade Air Mobility, Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityLow-Leverage Liquidity Configuration